Analysts See $-0.30 EPS for ConforMIS, Inc. (CFMS)

February 1, 2018 - By marketbeat

 Analysts See $ 0.30 EPS for ConforMIS, Inc. (CFMS)

Analysts expect ConforMIS, Inc. (NASDAQ:CFMS) to report $-0.30 EPS on February, 21.They anticipate $0.07 EPS change or 18.92 % from last quarter’s $-0.37 EPS. After having $-0.29 EPS previously, ConforMIS, Inc.’s analysts see 3.45 % EPS growth. The stock decreased 4.79% or $0.07 during the last trading session, reaching $1.39. About 665,799 shares traded or 6.77% up from the average. ConforMIS, Inc. (NASDAQ:CFMS) has declined 24.03% since February 1, 2017 and is downtrending. It has underperformed by 40.73% the S&P500.

ConforMIS, Inc. (NASDAQ:CFMS) Ratings Coverage

Among 10 analysts covering ConforMIS Inc (NASDAQ:CFMS), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. ConforMIS Inc had 27 analyst reports since July 27, 2015 according to SRatingsIntel. JP Morgan initiated it with “Overweight” rating and $28 target in Monday, July 27 report. The firm has “Buy” rating by SunTrust given on Monday, September 19. The stock has “Hold” rating by BTIG Research on Friday, July 14. JP Morgan downgraded ConforMIS, Inc. (NASDAQ:CFMS) on Tuesday, January 2 to “Underweight” rating. The rating was maintained by Oppenheimer with “Buy” on Friday, August 4. As per Wednesday, August 12, the company rating was maintained by Oppenheimer. As per Friday, May 13, the company rating was downgraded by Wells Fargo. The rating was downgraded by Deutsche Bank to “Hold” on Friday, August 4. JP Morgan maintained the stock with “Neutral” rating in Tuesday, August 9 report. The company was downgraded on Friday, May 13 by JP Morgan.

ConforMIS, Inc., a medical technology company, develops, makes, and sells customized joint replacement implants. The company has market cap of $81.82 million. The firm offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It currently has negative earnings. It is also developing iTotal Hip, a customized total hip replacement implant.

More important recent ConforMIS, Inc. (NASDAQ:CFMS) news were published by: Globenewswire.com which released: “ConforMIS Reports Preliminary Fourth Quarter and Year-End 2017 Revenue Results …” on January 08, 2018, also Globenewswire.com published article titled: “ConforMIS Announces Publication of Results published in the peer-reviewed …”, Globenewswire.com published: “ConforMIS Announces Pricing of Public Offering of Common Stock” on January 25, 2018. More interesting news about ConforMIS, Inc. (NASDAQ:CFMS) was released by: Streetinsider.com and their article: “ConforMIS Inc (CFMS) Prices 13.33M Shares Common Offering at $1.50/Sh” with publication date: January 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: